629 related articles for article (PubMed ID: 27017163)
1. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma.
Rezaee N; Barbon C; Zaki A; He J; Salman B; Hruban RH; Cameron JL; Herman JM; Ahuja N; Lennon AM; Weiss MJ; Wood LD; Wolfgang CL
HPB (Oxford); 2016 Mar; 18(3):236-46. PubMed ID: 27017163
[TBL] [Abstract][Full Text] [Related]
2. Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy.
Turrini O; Waters JA; Schnelldorfer T; Lillemoe KD; Yiannoutsos CT; Farnell MB; Sarr MG; Schmidt CM
HPB (Oxford); 2010 Sep; 12(7):447-55. PubMed ID: 20815853
[TBL] [Abstract][Full Text] [Related]
3. Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas.
Pea A; Yu J; Rezaee N; Luchini C; He J; Dal Molin M; Griffin JF; Fedor H; Fesharakizadeh S; Salvia R; Weiss MJ; Bassi C; Cameron JL; Zheng L; Scarpa A; Hruban RH; Lennon AM; Goggins M; Wolfgang CL; Wood LD
Ann Surg; 2017 Jul; 266(1):133-141. PubMed ID: 27433916
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for postoperative recurrence of intraductal papillary mucinous neoplasms of the pancreas based on a long-term follow-up study: proposals for follow-up strategies.
Yogi T; Hijioka S; Imaoka H; Mizuno N; Hara K; Tajika M; Tanaka T; Ishihara M; Shimizu Y; Hosoda W; Yatabe Y; Niwa Y; Yoshimura K; Bhatia V; Fujita J; Yamao K
J Hepatobiliary Pancreat Sci; 2015 Oct; 22(10):757-65. PubMed ID: 26148131
[TBL] [Abstract][Full Text] [Related]
6. Long-term prospective cohort study of patients undergoing pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: implications for postoperative surveillance.
Kang MJ; Jang JY; Lee KB; Chang YR; Kwon W; Kim SW
Ann Surg; 2014 Aug; 260(2):356-63. PubMed ID: 24378847
[TBL] [Abstract][Full Text] [Related]
7. Predictive Factors for the Metachronous Development of High-risk Lesions in the Remnant Pancreas After Partial Pancreatectomy for Intraductal Papillary Mucinous Neoplasm.
Miyasaka Y; Ohtsuka T; Tamura K; Mori Y; Shindo K; Yamada D; Takahata S; Ishigami K; Ito T; Tokunaga S; Oda Y; Mizumoto K; Nakamura M; Tanaka M
Ann Surg; 2016 Jun; 263(6):1180-7. PubMed ID: 26334637
[TBL] [Abstract][Full Text] [Related]
8. High-grade pancreatic intraepithelial lesions: prevalence and implications in pancreatic neoplasia.
Park JR; Li F; Oza VM; Sklaw BC; Cronley KM; Wellner M; Swanson B; Krishna SG
Hepatobiliary Pancreat Dis Int; 2017 Apr; 16(2):202-208. PubMed ID: 28381386
[TBL] [Abstract][Full Text] [Related]
9. Survival and prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas: comparison with pancreatic ductal adenocarcinoma.
Woo SM; Ryu JK; Lee SH; Yoo JW; Park JK; Kim YT; Yoon YB
Pancreas; 2008 Jan; 36(1):50-5. PubMed ID: 18192881
[TBL] [Abstract][Full Text] [Related]
10. Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage.
Waters JA; Schnelldorfer T; Aguilar-Saavedra JR; Chen JH; Yiannoutsos CT; Lillemoe KD; Farnell MB; Sarr MG; Schmidt CM
J Am Coll Surg; 2011 Aug; 213(2):275-83. PubMed ID: 21601488
[TBL] [Abstract][Full Text] [Related]
11. Dysplasia at the surgical margin is associated with recurrence after resection of non-invasive intraductal papillary mucinous neoplasms.
Frankel TL; LaFemina J; Bamboat ZM; D'Angelica MI; DeMatteo RP; Fong Y; Kingham TP; Jarnagin WR; Allen PJ
HPB (Oxford); 2013 Oct; 15(10):814-21. PubMed ID: 23782351
[TBL] [Abstract][Full Text] [Related]
12. Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: a retrospective review.
Tamura K; Ohtsuka T; Ideno N; Aso T; Shindo K; Aishima S; Ohuchida K; Takahata S; Ushijima Y; Ito T; Oda Y; Mizumoto K; Tanaka M
Ann Surg; 2014 Feb; 259(2):360-8. PubMed ID: 23989056
[TBL] [Abstract][Full Text] [Related]
13. Patterns of recurrence and long-term outcomes in patients who underwent pancreatectomy for intraductal papillary mucinous neoplasms with high grade dysplasia: implications for surveillance and future management guidelines.
Blackham AU; Doepker MP; Centeno BA; Springett G; Pimiento JM; Malafa M; Hodul PJ
HPB (Oxford); 2017 Jul; 19(7):603-610. PubMed ID: 28495434
[TBL] [Abstract][Full Text] [Related]
14. Resectable invasive IPMN versus sporadic pancreatic adenocarcinoma of the head of the pancreas: Should these two different diseases receive the same treatment? A matched comparison study of the French Surgical Association (AFC).
Duconseil P; Périnel J; Autret A; Adham M; Sauvanet A; Chiche L; Mabrut JY; Tuech JJ; Mariette C; Régenet N; Fabre JM; Bachellier P; Delpéro JR; Paye F; Turrini O
Eur J Surg Oncol; 2017 Sep; 43(9):1704-1710. PubMed ID: 28687431
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis index CD105 (endoglin)/CD31 (PECAM-1) as a predictive factor for invasion and proliferation in intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
Tachezy M; Reichelt U; Melenberg T; Gebauer F; Izbicki JR; Kaifi JT
Histol Histopathol; 2010 Oct; 25(10):1239-46. PubMed ID: 20712008
[TBL] [Abstract][Full Text] [Related]
16. High-grade dysplasia and adenocarcinoma are frequent in side-branch intraductal papillary mucinous neoplasm measuring less than 3 cm on endoscopic ultrasound.
Wong J; Weber J; Centeno BA; Vignesh S; Harris CL; Klapman JB; Hodul P
J Gastrointest Surg; 2013 Jan; 17(1):78-84; discussion p.84-5. PubMed ID: 22948841
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma.
Ideno N; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Tamura K; Aso T; Aishima S; Miyasaka Y; Ohuchida K; Ueda J; Takahata S; Oda Y; Mizumoto K; Tanaka M
Pancreas; 2015 Mar; 44(2):311-20. PubMed ID: 25479586
[TBL] [Abstract][Full Text] [Related]
18. The validity of the surgical indication for intraductal papillary mucinous neoplasm of the pancreas advocated by the 2017 revised International Association of Pancreatology consensus guidelines.
Watanabe Y; Endo S; Nishihara K; Ueda K; Mine M; Tamiya S; Nakano T; Tanaka M
Surg Today; 2018 Nov; 48(11):1011-1019. PubMed ID: 29961172
[TBL] [Abstract][Full Text] [Related]
19. Concomitant Intraductal Papillary Mucinous Neoplasm in Pancreatic Ductal Adenocarcinoma Is an Independent Predictive Factor for the Occurrence of New Cancer in the Remnant Pancreas.
Matsuda R; Miyasaka Y; Ohishi Y; Yamamoto T; Saeki K; Mochidome N; Abe A; Ozono K; Shindo K; Ohtsuka T; Kikutake C; Nakamura M; Oda Y
Ann Surg; 2020 May; 271(5):941-948. PubMed ID: 30308608
[TBL] [Abstract][Full Text] [Related]
20. Histopathological evaluation of resected intraductal papillary mucinous neoplasms reveals distinct patterns of invasion in associated carcinomas.
Rift CV; Lund EL; Scheie D; Hansen CP; Hasselby JP
Hum Pathol; 2021 Jul; 113():47-58. PubMed ID: 33915115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
